Idaho Technology said yesterday that it has changed its name to BioFire Diagnostics.
The Salt Lake City, Utah-based company said that the new name more accurately reflects its business strategy and "strong momentum in the marketplace."
BioFire will continue to develop multiplex diagnostic tests for various clinical applications on its FilmArray pathogen detection system. The company's US Food and Drug Administration-approved FilmArray Respiratory Panel is cleared for 20 viral and bacterial respiratory pathogens, eight of which aren't covered by any other FDA-cleared test (PCR Insider, 5/17/2012).
BioFire is also developing FilmArray panels for pathogen identification in blood culture, for which it initiated clinical trials last month (PCR Insider, 7/19/2012). It is also working on panels for gastrointestinal infections, meningitis, and other indications.
The company was also recently awarded a one-year, $262,000 grant from the National Institutes of Health to develop a FilmArray panel to detect pathogens causing pneumonia or other lower respiratory tract infections (PCR Insider, 7/26/2012).
The FilmArray platform integrates sample preparation, amplification, detection, and analysis, and is designed to provide results in about an hour with about two minutes of hands-on time, according to the company. The instrument performs PCR to initially amplify nucleic acids from target pathogens, and uses melt curve analysis for multiplexed detection.
BioFire said that it will continue develop biosurveillance products such as its PCR-based biodetection system RAZOR EX and the FilmArray BioSurveillance System.